Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 39 analyst ratings
Buy
Strong Buy 23%
Buy 38%
Hold 36%
Sell 3%
Strong Sell 0%

Bulls say

Edwards Lifesciences is projected to achieve robust revenue growth, with a 2025 estimate of $5.83 billion, reflecting a 9.2% year-over-year increase, driven significantly by transcatheter aortic valve replacement (TAVR) sales anticipated at $4.27 billion. The company's performance in TAVR is notably strong, with fourth-quarter 2023 sales reaching $1.04 billion, representing a 9.3% year-over-year increase, which surpassed expectations. Additionally, the anticipated growth in the worldwide transcatheter mitral and tricuspid therapies (TMTT) market, expected to expand to $5 billion, further bolsters Edwards Lifesciences's positive outlook in the healthcare sector.

Bears say

Edwards Lifesciences is facing a challenging financial outlook, with management forecasting Q1 2025 growth rates for total company sales and TAVR to fall below the lower bounds of their guidance ranges of 8-10% and 5-7% ex-FX, primarily due to one less selling day in the quarter. Additionally, various revenue growth headwinds, such as macroeconomic factors, slow adoption of TAVR, supply chain disruptions, and increased competition, could impede performance in the coming periods. The anticipated foreign exchange impact on sales could further exacerbate the situation, projected at a $130 million headwind, contributing to an overall negative outlook for the stock.

Edwards Lifesciences (EW) has been analyzed by 39 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 38% recommend Buy, 36% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 39 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.